Epidemiology and etiology of meningioma

Joseph Wiemels, Margaret Wrensch, Elizabeth B Claus, Joseph Wiemels, Margaret Wrensch, Elizabeth B Claus

Abstract

Although most meningiomas are encapsulated and benign tumors with limited numbers of genetic aberrations, their intracranial location often leads to serious and potentially lethal consequences. They are the most frequently diagnosed primary brain tumor accounting for 33.8% of all primary brain and central nervous system tumors reported in the United States between 2002 and 2006. Inherited susceptibility to meningioma is suggested both by family history and candidate gene studies in DNA repair genes. People with certain mutations in the neurofibromatosis gene (NF2) have a very substantial increased risk for meningioma. High dose ionizing radiation exposure is an established risk factor for meningioma, and lower doses may also increase risk, but which types and doses are controversial or understudied. Because women are twice as likely as men to develop meningiomas and these tumors harbor hormone receptors, an etiologic role for hormones (both endogenous and exogenous) has been hypothesized. The extent to which immunologic factors influence meningioma etiology has been largely unexplored. Growing emphasis on brain tumor research coupled with the advent of new genetic and molecular epidemiologic tools in genetic and molecular epidemiology promise hope for advancing knowledge about the causes of intra-cranial meningioma. In this review, we highlight current knowledge about meningioma epidemiology and etiology and suggest future research directions.

Figures

Fig. 1
Fig. 1
Age and gender-specific incidence rates (per 100,000 population) for meningioma in the United States (2002–2006) (from reference 4). The left Y-axis scale refers to the bar graphs. The ratio of female to male incidence is indicated by a diamond at each age group, and the axis for the ratio is along the right hand side of the figure. The peak ratio of 3.15, female:male, is among the 35–44 year age group

References

    1. Sadetzki S, Modan B, Chetrit A, Freedman L. An iatrogenic epidemic of benign meningioma. Am J Epidemiol. 2000;151:266–272.
    1. Krampla W, Newrkla S, Pfisterer W, Jungwirth S, Fischer P, Leitha T, Hruby W, Tragl KH. Frequency and risk factors for meningioma in clinically healthy 75-year-old patients: results of the Transdanube Ageing Study (VITA) Cancer. 2004;100:1208–1212. doi: 10.1002/cncr.20088.
    1. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, Niessen WJ, Breteler MM, van der Lugt A. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357:1821–1828. doi: 10.1056/NEJMoa070972.
    1. Group TIS Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case–control study. Int J Epidemiol. 2010;39:675–694. doi: 10.1093/ije/dyq079.
    1. Benson VS, Pirie K, Green J, Casabonne D, Beral V. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer. 2008;99:185–190. doi: 10.1038/sj.bjc.6604445.
    1. Berg-Beckhoff G, Schuz J, Blettner M, Munster E, Schlaefer K, Wahrendorf J, Schlehofer B. History of allergic disease and epilepsy and risk of glioma and meningioma (INTERPHONE study group, Germany) Eur J Epidemiol. 2009;24:433–440. doi: 10.1007/s10654-009-9355-6.
    1. Schoemaker MJ, Swerdlow AJ, Hepworth SJ, van Tongeren M, Muir KR, McKinney PA. History of allergic disease and risk of meningioma. Am J Epidemiol. 2007;165:477–485. doi: 10.1093/aje/kwk048.
    1. Wigertz A, Lonn S, Schwartzbaum J, Hall P, Auvinen A, Christensen HC, Johansen C, Klaeboe L, Salminen T, Schoemaker MJ, Swerdlow AJ, Tynes T, Feychting M. Allergic conditions and brain tumor risk. Am J Epidemiol. 2007;166:941–950. doi: 10.1093/aje/kwm203.
    1. CBTRUS (2009–2010) CDTRUS Statistical Report: promary brain and central nervous system tumors diagnosed in eighteeen states in 2002–2006. Central Brain Tumor Registry of the United States, Hisdale
    1. Li X, Zhao J. Intracranial meningiomas of childhood and adolescence: report of 34 cases with follow-up. Childs Nerv Syst. 2009;25:1411–1417. doi: 10.1007/s00381-009-0949-9.
    1. Menon G, Nair S, Sudhir J, Rao BR, Mathew A, Bahuleyan B. Childhood and adolescent meningiomas: a report of 38 cases and review of literature. Acta Neurochir (Wien) 2009;151:239–244. doi: 10.1007/s00701-009-0206-8.
    1. Al Saadi A, Latimer F, Madercic M, Robbins T. Cytogenetic studies of human brain tumors and their clinical significance. II. Meningioma. Cancer Genet Cytogenet. 1987;26:127–141. doi: 10.1016/0165-4608(87)90140-3.
    1. Hansson CM, Buckley PG, Grigelioniene G, Piotrowski A, Hellstrom AR, Mantripragada K, Jarbo C, Mathiesen T, Dumanski JP. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. BMC Genomics. 2007;8:16. doi: 10.1186/1471-2164-8-16.
    1. Shen Y, Nunes F, Stemmer-Rachamimov A, James M, Mohapatra G, Plotkin S, Betensky RA, Engler DA, Roy J, Ramesh V, Gusella JF. Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics. 2009;2:42. doi: 10.1186/1755-8794-2-42.
    1. Ragel BT, Jensen RL. Molecular genetics of meningiomas. Neurosurg Focus. 2005;19:E9. doi: 10.3171/foc.2005.19.5.10.
    1. Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. Genomic landscape of meningiomas. Brain Pathol. 2009;20:751–762. doi: 10.1111/j.1750-3639.2009.00356.x.
    1. Simon M, Bostrom JP, Hartmann C. Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery. 2007;60:787–798. doi: 10.1227/.
    1. Jun P, Hong C, Lal A, Wong JM, McDermott MW, Bollen AW, Plass C, Held WA, Smiraglia DJ, Costello JF. Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific. Neuro Oncol. 2009;11:414–422. doi: 10.1215/15228517-2008-096.
    1. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006;5:1045–1054. doi: 10.1016/S1474-4422(06)70625-1.
    1. Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, Razzouk BI, Ribeiro RC, Rubnitz JE, Sandlund JT, Rivera GK, Evans WE, Relling MV, Pui CH. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297:1207–1215. doi: 10.1001/jama.297.11.1207.
    1. Preston DL, Ron E, Yonehara S, Kobuke T, Fujii H, Kishikawa M, Tokunaga M, Tokuoka S, Mabuchi K. Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst. 2002;94:1555–1563.
    1. Ron E, Modan B, Boice JD, Jr, Alfandary E, Stovall M, Chetrit A, Katz L. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033–1039. doi: 10.1056/NEJM198810203191601.
    1. Sadetzki S, Flint-Richter P, Starinsky S, Novikov I, Lerman Y, Goldman B, Friedman E. Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarkers Prev. 2005;14:969–976. doi: 10.1158/1055-9965.EPI-04-0366.
    1. Sadetzki S, Flint-Richter P, Ben-Tal T, Nass D. Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg. 2002;97:1078–1082. doi: 10.3171/jns.2002.97.5.1078.
    1. Preston-Martin S. Descriptive epidemiology of primary tumors of the spinal cord and spinal meninges in Los Angeles County, 1972–1985. Neuroepidemiology. 1990;9:106–111. doi: 10.1159/000110757.
    1. Ryan P, Lee MW, North B, McMichael AJ. Amalgam fillings, diagnostic dental X-rays and tumours of the brain and meninges. Eur J Cancer B Oral Oncol. 1992;28B:91–95. doi: 10.1016/0964-1955(92)90034-X.
    1. Schlehofer B, Blettner M, Becker N, Martinsohn C, Wahrendorf J. Medical risk factors and the development of brain tumors. Cancer. 1992;69:2541–2547. doi: 10.1002/1097-0142(19920515)69:10<2541::AID-CNCR2820691025>;2-H.
    1. Longstreth WT, Jr, Phillips LE, Drangsholt M, Koepsell TD, Custer BS, Gehrels JA, van Belle G. Dental X-rays and the risk of intracranial meningioma: a population-based case–control study. Cancer. 2004;100:1026–1034. doi: 10.1002/cncr.20036.
    1. Claus EB, Black PM, Bondy ML, Calvocoressi L, Schildkraut JM, Wiemels JL, Wrensch M. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer. 2007;110:471–476. doi: 10.1002/cncr.22783.
    1. Vadivelu S, Sharer L, Schulder M. Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy. J Neurosurg. 2010;112:920–924. doi: 10.3171/2009.8.JNS09201.
    1. Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? J Clin Oncol. 2008;26:279–282. doi: 10.1200/JCO.2007.14.2133.
    1. Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F. Association of meningioma with reproductive factors. Int J Cancer. 2006;119:1152–1157. doi: 10.1002/ijc.21950.
    1. Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol. 2006;164:629–636. doi: 10.1093/aje/kwj254.
    1. Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ. Sex steroid hormone exposures and risk for meningioma. J Neurosurg. 2003;99:848–853. doi: 10.3171/jns.2003.99.5.0848.
    1. Wigertz A, Lonn S, Hall P, Auvinen A, Christensen HC, Johansen C, Klaeboe L, Salminen T, Schoemaker MJ, Swerdlow AJ, Tynes T, Feychting M. Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev. 2008;17:2663–2670. doi: 10.1158/1055-9965.EPI-08-0406.
    1. Lambe M, Coogan P, Baron J. Reproductive factors and the risk of brain tumors: a population-based study in Sweden. Int J Cancer. 1997;72:389–393. doi: 10.1002/(SICI)1097-0215(19970729)72:3<389::AID-IJC2>;2-L.
    1. Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol. 2006;80:1–7. doi: 10.1007/s11060-006-9146-9.
    1. Custer B, Longstreth WT, Jr, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case–control study. BMC Cancer. 2006;6:152. doi: 10.1186/1471-2407-6-152.
    1. Black P, Carroll R, Zhang J. The molecular biology of hormone and growth factor receptors in meningiomas. Acta Neurochir Suppl. 1996;65:50–53.
    1. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg. 1997;86:113–120. doi: 10.3171/jns.1997.86.1.0113.
    1. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN. Expression of androgen and progesterone receptors in primary human meningiomas. J Neurosurg. 1993;78:456–462. doi: 10.3171/jns.1993.78.3.0456.
    1. Claus EB, Park PJ, Carroll R, Chan J, Black PM. Specific genes expressed in association with progesterone receptors in meningioma. Cancer Res. 2008;68:314–322. doi: 10.1158/0008-5472.CAN-07-1796.
    1. Phillips LE, Koepsell TD, van Belle G, Kukull WA, Gehrels JA, Longstreth WT., Jr History of head trauma and risk of intracranial meningioma: population-based case–control study. Neurology. 2002;58:1849–1852.
    1. Preston-Martin S, Paganini-Hill A, Henderson BE, Pike MC, Wood C. Case–control study of intracranial meningiomas in women in Los Angeles County, California. J Natl Cancer Inst. 1980;65:67–73.
    1. Annegers JF, Laws ER, Jr, Kurland LT, Grabow JD. Head trauma and subsequent brain tumors. Neurosurgery. 1979;4:203–206. doi: 10.1227/00006123-197903000-00001.
    1. Eskandary H, Sabba M, Khajehpour F, Eskandari M. Incidental findings in brain computed tomography scans of 3000 head trauma patients. Surg Neurol. 2005;63:550–553. doi: 10.1016/j.surneu.2004.07.049.
    1. Inskip PD, Mellemkjaer L, Gridley G, Olsen JH. Incidence of intracranial tumors following hospitalization for head injuries (Denmark) Cancer Causes Control. 1998;9:109–116. doi: 10.1023/A:1008861722901.
    1. Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Shapiro WR, Selker RG, Fine HA, Black PM, Loeffler JS, Linet MS. Cellular-telephone use and brain tumors. N Engl J Med. 2001;344:79–86. doi: 10.1056/NEJM200101113440201.
    1. Johansen C, Boice J, Jr, McLaughlin J, Olsen J. Cellular telephones and cancer–a nationwide cohort study in Denmark. J Natl Cancer Inst. 2001;93:203–207. doi: 10.1093/jnci/93.3.203.
    1. Muscat JE, Malkin MG, Thompson S, Shore RE, Stellman SD, McRee D, Neugut AI, Wynder EL. Handheld cellular telephone use and risk of brain cancer. JAMA. 2000;284:3001–3007. doi: 10.1001/jama.284.23.3001.
    1. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, Yasui Y, Kasper CE, Mertens AC, Donaldson SS, Meadows AT, Inskip PD. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98:1528–1537. doi: 10.1093/jnci/djj411.
    1. Bethke L, Murray A, Webb E, Schoemaker M, Muir K, McKinney P, Hepworth S, Dimitropoulou P, Lophatananon A, Feychting M, Lonn S, Ahlbom A, Malmer B, Henriksson R, Auvinen A, Kiuru A, Salminen T, Johansen C, Christensen HC, Kosteljanetz M, Swerdlow A, Houlston R. Comprehensive analysis of DNA repair gene variants and risk of meningioma. J Natl Cancer Inst. 2008;100:270–276. doi: 10.1093/jnci/djn004.
    1. Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer. 2002;94:1626–1635. doi: 10.1002/cncr.10410.
    1. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57:1088–1095. doi: 10.1227/01.NEU.0000188281.91351.B9.
    1. Terry MB, Howe G, Pogoda JM, Zhang FF, Ahlbom A, Choi W, Giles GG, Little J, Lubin F, Menegoz F, Ryan P, Schlehofer B, Preston-Martin S. An international case–control study of adult diet and brain tumor risk: a histology-specific analysis by food group. Ann Epidemiol. 2009;19:161–171. doi: 10.1016/j.annepidem.2008.12.010.
    1. Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer. 2002;99:252–259. doi: 10.1002/ijc.10320.
    1. Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst. 2007;99:1544–1550. doi: 10.1093/jnci/djm170.
    1. Rajaraman P, Brenner AV, Neta G, Pfeiffer R, Wang SS, Yeager M, Thomas G, Fine HA, Linet MS, Rothman N, Chanock SJ, Inskip PD. Risk of meningioma and common variation in genes related to innate immunity. Cancer Epidemiol Biomarkers Prev. 2010;19:1356–1361. doi: 10.1158/1055-9965.EPI-09-1151.
    1. Malmer B, Henriksson R, Gronberg H. Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. Int J Cancer. 2003;106:260–263. doi: 10.1002/ijc.11213.
    1. Hemminki K, Tretli S, Sundquist J, Johannesen TB, Granstrom C. Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway. Lancet Oncol. 2009;10:481–488. doi: 10.1016/S1470-2045(09)70076-2.
    1. Malmer BS, Feychting M, Lonn S, Lindstrom S, Gronberg H, Ahlbom A, Schwartzbaum J, Auvinen A, Collatz-Christensen H, Johansen C, Kiuru A, Mudie N, Salminen T, Schoemaker MJ, Swerdlow AJ, Henriksson R. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 2007;82:229–237. doi: 10.1007/s11060-006-9275-1.
    1. Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Chanock SJ, Inskip PD. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 2007;16:1655–1661. doi: 10.1158/1055-9965.EPI-07-0314.
    1. Lai R, Crevier L, Thabane L. Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:1784–1790. doi: 10.1158/1055-9965.EPI-05-0105.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する